PSA lo and behold: prostate cancer stem cells.

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

Who cites it

4 citing papers in PubMed.

1. Stemness regulation in prostate cancer: prostate cancer stem cells and targeted therapy.Annals of medicine · 2025
   Review
2. Blockade of ACK1/TNK2 To Squelch the Survival of Prostate Cancer Stem-like Cells.Scientific reports · 2018
   Article
3. Loss of androgen receptor expression promotes a stem-like cell phenotype in prostate cancer through STAT3 signaling.Cancer research · 2014
   Article
4. Cancer Stem Cells Decide the Fate of Cancer Immunotherapy by Remodeling Tumor Microenvironment.Cancer control : journal of the Moffitt Cancer Center
   Review

Corrections and comments

• Comment on
  The PSA(-/lo) prostate cancer cell population harbors self-renewing long-term tumor-propagating cells that resist castration.2012

Authors and funding

1 author.

Funding

Abstract